$GSHD

GOOSEHEAD INSURANCE, INC. ANNOUNCES SECOND QUARTER 2026 RESULTS

Goosehead Insurance, Inc. (GSHD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a20260630-earningsrelease1.htm EX-99.1 Document GOOSEHEAD INSURANCE, INC. ANNOUNCES SECOND QUARTER 2026 RESULTS – Total Revenue Increased 21% and Core Revenue* Grew 10% over the Prior-Year Period – – Total Written Premium increased 14% to $1.34 billion over the Prior-Ye

Original reporting
Published Jul 22, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GSHD
Bullish
high confidence
Mentioned
$GSHD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GSHDBullishHigh
01

Why it matters

Traders can update forward revenue and written-premium assumptions using the raised organic growth and premium growth ranges, and reassess valuation versus peers on agency productivity and retention.

02

Market read

Raised full-year guidance plus strong Q2 operating metrics (premiums, policies in force, retention, adjusted EBITDA margin) create a clear catalyst for estimate revisions.

03

What to watch

Liquidity is modest (cash $23.7M) versus notes payable ($323.0M) and a drawn revolver; watch whether future growth requires higher leverage or margin compression.

Relevance 7/10Novelty 9/10Timing: after-hours guidance raise and Q2 print filed on SEC 8-K

Background

The 8-K (Item 2.02) attaches Goosehead’s Q2 2026 results release and includes an updated 2026 outlook.

Company-level read

Ticker impact

$GSHDBullishHigh confidence
Context

Goosehead reported Q2 2026 results with 21% revenue growth, $1.34B written premiums (+14%), and raised full-year guidance ranges.

Expected impact

Likely positive bias for the next few sessions as guidance-updated models reprice; magnitude depends on how the market compares the new ranges to consensus.

Evidence & confidence

The filing includes specific, time-sensitive datapoints (Q2 financials and explicit guidance increases for revenues and written premiums), which are direct inputs to forward earnings expectations.

Market effects

Reinforces demand/read-through for independent personal lines agencies, especially around policy growth, retention, and distribution productivity.

No explicit regional catalyst beyond company operations; impact is primarily company-specific.

Limited global relevance; US personal lines agency growth story.

Counterpoint

Premium growth and profitability could be partially driven by timing and non-GAAP adjustments; investors may discount if expense growth or variable consideration dynamics reappear.

Key entities

  • Goosehead Insurance, Inc.

    Independent personal lines insurance agency reporting Q2 2026 results and raising full-year 2026 guidance.

  • Mark Miller

    CEO quoted in the release describing accelerating momentum and favorable product market conditions.

Related articles

$SDEVMed

Stablecoin Development Corp (SDEV): Results of Operations and Financial Condition

Stablecoin Development Corp (SDEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 OUR BUSINESS The following disclosure supplements the descriptions of Stablecoin Development Corporation’s (“SDEV,” the “company” or the “Company,” “we,” “us,” or “our”) business contained in our Annual Report on Form 10-K for the year ended December 31, 2025, filed

$TSLAMedAI 8/10

Tesla Beat on Deliveries. Why the Upside Case Is Only 9%

Tesla (TSLA) reported better-than-expected Q3 vehicle deliveries, leading to a 4.88% intraday share price increase. The company's 24/7 Wall St. price target is $387.23, a 9.35% upside from the reference price. Despite strong delivery numbers, Tesla faces challenges with shrinking margins and high valuation. Analysts have mixed views on the stock's future performance, with bull and bear cases presenting different price targets.

$BBBYWMed

NEIGHBORHOOD INTELLIGENCE, INC. (BBBYW): Results of Operations and Financial Condition

NEIGHBORHOOD INTELLIGENCE, INC. (BBBYW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fathom Holdings and Neighborhood Intelligence Announce Mutual Termination of Proposed Merger Boards conclude that current valuations do not reflect the fair value of either company; Neighborhood Intelligence to retain blockchain asset ownership while the companies ex

$GMABMed

Guggenheim raises Genmab stock price target on pipeline potential

Guggenheim raised its price target for Genmab (NASDAQ:GMAB) to $54 from $45, citing confidence in its R&D pipeline, including Rina-S. The stock is near its 52-week high and has gained 26% in six months. Genmab reported Q2 2026 earnings of $4.91 per share, exceeding estimates, and raised 2026 revenue guidance to DKK 4.3-4.5 billion. H.C. Wainwright maintains a Buy rating with a $40 target.

$ROIVMedAI 8/10

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.